Highlighting Key Trials in Kidney Cancer

In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.

Pembrolizumab consistently improves overall and disease-free survival in clear cell renal cell carcinoma, showing sustained benefit at 5 years post surgery.

In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.

Combining sasanlimab with BCG significantly enhances event-free survival in high-risk non-muscle invasive bladder cancer, especially in CIS patients.

A groundbreaking trial explores pembrolizumab's role in enhancing treatment outcomes for advanced head and neck cancer, promising significant advancements in patient care.